Alleged receiving of kickbacks by senior executives in China could subject Adidas to Chinese, as well as German and U.S. investigations; U.S. convertible bond market is used to raise funds by Chinese big tech amid IPO restrictions; and EU tariffs may lead to localization of Chinese EV production.
Philip Qu and Qiuchen Wang from TransAsia Lawyers analyze a pioneering approach to regulating cross-border data transfers recently adopted in one of Shanghai's free trade zones
International investors find Chinese secondary PE market an alternative amid U.S.-China tensions; QuantumPharm is the first IPO under Hong Kong's new measure for pre-revenue specialist technology firms; and China releases new carbon measuring standards foreseeing new EU carbon tariffs.
Western companies are investing in Chinese biotech even amid continued geopolitical tension between China and the West and decreasing appetite for foreign investment in China; Two lithium battery part manufacturers, Capchem and Kedaliplan, plan to build factories in the U.S. to avoid hefty lithium battery tariffs; and Chinese pharma firm Asymchem to take over U.K. Pfizer plant.
Shanghai FTZ expedites cross-border transfer of specified data; CBP investigation finds no substantial evidence of evasion by CIE; and Another Chinese EV SPAC merger is in the pipeline but EU tariffs threaten the business.
Charles Wu of Clyde & Co describes the current regulatory state of China's investment market, for private equity investors, including the much anticipated recent clarity provided by key regulators as well as potential pitfalls to avoid
Successful U.S. IPO of Chinese EV brand suggests rising investor confidence, but regulatory risks still loom; Burberry wins trademark infringement and unfair competition lawsuit; and China proposes guidelines to it's lithium battery sector amid overcapacity concerns.
